Article Test

Home  >  Medical Research Archives  >  Issue 149  > Acetylcholinesterase Inhibitors for Alzheimer’s disease: Past, Present, and Potential Future
Published in the Medical Research Archives
Dec 2020 Issue

Acetylcholinesterase Inhibitors for Alzheimer’s disease: Past, Present, and Potential Future

Published on Dec 18, 2020

DOI 

Abstract

 

Alzheimer’s Diseases (AD) is a neurodegenerative disorder characterized by progressive neuronal loss leading to cognitive decline. Although there is yet to be a cure nor a way to reverse the neuronal damage, there are current treatments to amend some of the cognitive symptoms associated with AD. Acetylcholinesterase inhibitors (AChEi) are the primary agents of choice and have had profound implications throughout the past decades. AChEi such as donepezil, rivastigmine, and galantamine mediates and increases cholinergic activities in the central nervous system (CNS), and have been shown to improve and preserve cognition in AD patients. Beyond the current drugs on the market, investigational discoveries continue to explore the potential of safer and more efficacious AChEi agents for the treatment of AD. There have been quite a few challenges, given the high failure rates. Yet, these very trials and studies have been a fundamental step towards better understanding the treatments of AD and have provided some insight on the potential to surpass what is currently available.  

Author info

Ronny Priefer, Brandon Truong, Jose Quiroz

Have an article to submit?

Submission Guidelines

Submit a manuscript

Become a member

Call for papers

Have a manuscript to publish in the society's journal?